期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Clinical progress of nanomedicine-based RNA therapies
1
作者 Siyoung A.Lim Alysia Cox +1 位作者 madelynn tung Eun Ji Chung 《Bioactive Materials》 SCIE 2022年第6期203-213,共11页
The clinical application of nanoparticles(NPs)to deliver RNA for therapy has progressed rapidly since the FDA approval of Onpattro®in 2018 for the treatment of polyneuropathy associated with hereditary transthyre... The clinical application of nanoparticles(NPs)to deliver RNA for therapy has progressed rapidly since the FDA approval of Onpattro®in 2018 for the treatment of polyneuropathy associated with hereditary transthyretin amyloidosis.The emergency use authorization or approval and widespread global use of two mRNA-NP based vaccines developed by Moderna Therapeutics Inc.and Pfizer-BioNTech in 2021 has highlighted the translatability of NP technology for RNA delivery.Furthermore,in clinical trials,a wide variety of NP formulations have been found to extend the half-life of RNA molecules such as microRNA,small interfering RNA,and messenger RNA,with limited safety issues.In this review,we discuss the NP formulations that are already used in the clinic to deliver therapeutic RNA and highlight examples of RNA-NPs which are currently under evaluation for human use.We also detail NP formulations that failed to progress through clinical trials,in hopes of guiding future successful translation of nanomedicine-based RNA therapeutics into the clinic. 展开更多
关键词 Nanoparticles RNA therapy Drug delivery NANOMEDICINE Clinical trials COVID-19
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部